PDF(Pubmed)
Abstract：
UNASSIGNED: The use of botanical medicine has been demonstrated as a potential strategy to manage or treat a variety of health issues. Terminalia chebula (Retz) fruit and Withania somnifera (L.) Dunal roots are important medicinal herbs described in Ayurveda and traditional therapy for diverse health benefits.
UNASSIGNED: This pilot study aimed to evaluate the immune function-enhancing potential of a unique blend of T. chebula fruit and W. somnifera root extracts, LN20189, in healthy men and women.
UNASSIGNED: Forty healthy volunteers (age: 35-60 years) were randomized into two groups receiving either LN20189 (500 mg per day) or a matched placebo over 28 consecutive days. The total T-cell population was the primary efficacy measure in this study. The secondary efficacy measures included counts of CD4, CD8, natural killer (NK) cells, serum levels of interleukin-2 (IL-2), interferon-gamma (IFN-γ), total immunoglobulin-G (IgG), and Immune Function Questionnaire (IFQ) scores. Safety parameter assessments were also conducted.
UNASSIGNED: Post-trial, in LN20189-supplemented subjects, T cells, CD4, NK cells count, and the CD4:CD8 ratio were increased by 9.32, 10.10, 19.91, and 17.43%, respectively, as compared to baseline. LN20189 supplementation increased serum IFN-γ and IgG levels by 14.57 and 27.09% from baseline and by 13.98 and 21.99%, compared to placebo, respectively. Also, the IFQ scores in the LN20189 group were 84.68% (vs. baseline) and 69.44% (vs. placebo) lower at the end of the trial. LN20189 improved the study volunteers\' cellular and humoral immune functions.
UNASSIGNED: In summary, LN20189 supplementation was found tolerable and improved the key cellular and humoral factors of the immune system and helped improve immune function of the trial volunteers.
UNASSIGNED: This pilot study aimed to evaluate the immune function-enhancing potential of a unique blend of T. chebula fruit and W. somnifera root extracts, LN20189, in healthy men and women.
UNASSIGNED: Forty healthy volunteers (age: 35-60 years) were randomized into two groups receiving either LN20189 (500 mg per day) or a matched placebo over 28 consecutive days. The total T-cell population was the primary efficacy measure in this study. The secondary efficacy measures included counts of CD4, CD8, natural killer (NK) cells, serum levels of interleukin-2 (IL-2), interferon-gamma (IFN-γ), total immunoglobulin-G (IgG), and Immune Function Questionnaire (IFQ) scores. Safety parameter assessments were also conducted.
UNASSIGNED: Post-trial, in LN20189-supplemented subjects, T cells, CD4, NK cells count, and the CD4:CD8 ratio were increased by 9.32, 10.10, 19.91, and 17.43%, respectively, as compared to baseline. LN20189 supplementation increased serum IFN-γ and IgG levels by 14.57 and 27.09% from baseline and by 13.98 and 21.99%, compared to placebo, respectively. Also, the IFQ scores in the LN20189 group were 84.68% (vs. baseline) and 69.44% (vs. placebo) lower at the end of the trial. LN20189 improved the study volunteers\' cellular and humoral immune functions.
UNASSIGNED: In summary, LN20189 supplementation was found tolerable and improved the key cellular and humoral factors of the immune system and helped improve immune function of the trial volunteers.
摘要：
■使用植物药已被证明是管理或治疗各种健康问题的潜在策略。Terminaliachebula（Retz）水果和Withaniasomnifera（L.）Dunal根是阿育吠陀和传统疗法中描述的重要草药，具有多种健康益处。
■这项初步研究旨在评估T.chebula果实和W.somnifera根提取物的独特混合物的免疫功能增强潜力，LN20189，健康男性和女性。
■将40名健康志愿者（年龄：35-60岁）随机分为两组，连续28天接受LN20189（每天500mg）或匹配的安慰剂。总T细胞群体是本研究中的主要功效量度。次要疗效指标包括CD4，CD8，自然杀伤（NK）细胞计数，血清白细胞介素-2（IL-2）水平，干扰素-γ（IFN-γ），总免疫球蛋白G（IgG），免疫功能问卷(IFQ)评分。还进行了安全性参数评估。
■审判后，在LN20189补充的科目中，T细胞,CD4,NK细胞计数,CD4：CD8比值分别增加了9.32、10.10、19.91和17.43%，分别,与基线相比。LN20189补充血清IFN-γ和IgG水平从基线增加了14.57和27.09％，分别增加了13.98和21.99％，与安慰剂相比，分别。此外，LN20189组的IFQ评分为84.68%(与基线)和69.44%(与安慰剂)在试验结束时降低。LN20189改善了研究志愿者的细胞和体液免疫功能。
■总之，发现LN20189补充剂是可耐受的，并改善了免疫系统的关键细胞和体液因子，并有助于改善试验志愿者的免疫功能。
■这项初步研究旨在评估T.chebula果实和W.somnifera根提取物的独特混合物的免疫功能增强潜力，LN20189，健康男性和女性。
■将40名健康志愿者（年龄：35-60岁）随机分为两组，连续28天接受LN20189（每天500mg）或匹配的安慰剂。总T细胞群体是本研究中的主要功效量度。次要疗效指标包括CD4，CD8，自然杀伤（NK）细胞计数，血清白细胞介素-2（IL-2）水平，干扰素-γ（IFN-γ），总免疫球蛋白G（IgG），免疫功能问卷(IFQ)评分。还进行了安全性参数评估。
■审判后，在LN20189补充的科目中，T细胞,CD4,NK细胞计数,CD4：CD8比值分别增加了9.32、10.10、19.91和17.43%，分别,与基线相比。LN20189补充血清IFN-γ和IgG水平从基线增加了14.57和27.09％，分别增加了13.98和21.99％，与安慰剂相比，分别。此外，LN20189组的IFQ评分为84.68%(与基线)和69.44%(与安慰剂)在试验结束时降低。LN20189改善了研究志愿者的细胞和体液免疫功能。
■总之，发现LN20189补充剂是可耐受的，并改善了免疫系统的关键细胞和体液因子，并有助于改善试验志愿者的免疫功能。
